June 11, 2021Treatment with delayed-release and extended-release methylphenidate (DR/ER-MPH) led to clinically meaningful improvements in functional impairment in children with ADHD compared to placebo.
This study, which demonstrated significant improvements in before- and after-school impairments, was published in the Journal of Attention Disorders and funded by Ironshore Pharmaceuticals, maker of Jornay PM, an ER-MPH taken at night.1The data source for this study was a post hoc analysis based on data from a randomized, double-blind, multi-center, placebo-controlled trial of DR/ER-MPH in 161 children with diagnosed ADHD.
Read more on additudemag.com